Total Payments
$43,943
2024 Payments
$6,330
Companies
36
Transactions
136
Medicare Patients
1,210
Medicare Billing
$221,004
Payment Breakdown by Category
Other$27,650 (62.9%)
Consulting$6,882 (15.7%)
Food & Beverage$4,587 (10.4%)
Travel$4,272 (9.7%)
Research$523.07 (1.2%)
Education$28.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,775 | 10 | 54.1% |
| Consulting Fee | $6,882 | 5 | 15.7% |
| Food and Beverage | $4,587 | 101 | 10.4% |
| Travel and Lodging | $4,272 | 10 | 9.7% |
| Honoraria | $3,875 | 3 | 8.8% |
| Unspecified | $523.07 | 5 | 1.2% |
| Education | $28.62 | 2 | 0.1% |
Payments by Type
General
$43,420
131 transactions
Research
$523.07
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $25,982 | 40 | $0 (2019) |
| Ipsen Biopharmaceuticals, Inc | $3,450 | 2 | $0 (2024) |
| Amgen Inc. | $2,823 | 9 | $0 (2023) |
| ABBVIE INC. | $2,396 | 10 | $0 (2024) |
| GENZYME CORPORATION | $2,207 | 3 | $0 (2024) |
| ADC Therapeutics America, Inc. | $2,197 | 3 | $0 (2023) |
| MorphoSys, US Inc. | $1,455 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $793.07 | 7 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $388.39 | 5 | $0 (2023) |
| Tempus AI, Inc | $354.29 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,330 | 21 | Ipsen Biopharmaceuticals, Inc ($3,450) |
| 2023 | $1,686 | 24 | Novartis Pharmaceuticals Corporation ($657.14) |
| 2022 | $1,759 | 6 | MorphoSys, US Inc. ($1,455) |
| 2021 | $4,033 | 5 | ADC Therapeutics America, Inc. ($2,109) |
| 2020 | $212.41 | 10 | Coherus Biosciences Inc. ($75.00) |
| 2019 | $639.93 | 25 | Janssen Biotech, Inc. ($151.93) |
| 2018 | $17,838 | 25 | Janssen Pharmaceuticals, Inc ($14,738) |
| 2017 | $11,444 | 20 | Janssen Pharmaceuticals, Inc ($11,210) |
All Payment Transactions
136 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Honoraria | Cash or cash equivalent | $1,725.00 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 09/05/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $40.42 | General |
| 08/15/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.32 | General |
| Category: Hematology | ||||||
| 06/27/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.33 | General |
| Category: Hematology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: Immunology | ||||||
| 06/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $96.63 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $32.68 | General |
| Category: Hematology | ||||||
| 05/08/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $94.05 | General |
| 05/08/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: Rare Disease | ||||||
| 04/25/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Oncology | ||||||
| 04/23/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,977.00 | General |
| 04/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: BioOncology | ||||||
| 03/21/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $25.80 | General |
| 02/23/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $94.02 | General |
| 02/20/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: Rare Disease | ||||||
| 02/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.78 | General |
| Category: Hematology | ||||||
| 12/12/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $6.91 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $120.02 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | AbbVie Inc. | — | — | In-kind items and services | $69.76 | Research |
| Study: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | ||||||
| 12/08/2023 | AbbVie Inc. | — | — | In-kind items and services | $59.75 | Research |
| Study: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | AbbVie Inc. | $523.07 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 231 | 599 | $92,497 | $48,051 |
| 2022 | 6 | 229 | 593 | $116,808 | $52,524 |
| 2021 | 8 | 326 | 711 | $136,735 | $68,158 |
| 2020 | 14 | 424 | 641 | $118,274 | $52,273 |
Total Patients
1,210
Total Services
2,544
Medicare Billing
$221,004
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 94 | 296 | $55,559 | $24,662 | 44.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 82 | 214 | $20,972 | $15,777 | 75.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 27 | $6,828 | $3,446 | 50.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 29 | $5,530 | $2,626 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 22 | $2,865 | $1,033 | 36.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 11 | $742.50 | $506.50 | 68.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 418 | $81,928 | $37,579 | 45.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 26 | 45 | $12,105 | $5,942 | 49.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 40 | $7,840 | $3,114 | 39.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 37 | $4,995 | $2,129 | 42.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 38 | $5,320 | $2,059 | 38.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $4,620 | $1,702 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 124 | 365 | $63,875 | $34,450 | 53.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 50 | 116 | $27,840 | $14,371 | 51.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 65 | $12,025 | $5,162 | 42.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 25 | $8,500 | $3,758 | 44.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 27 | 62 | $8,680 | $3,424 | 39.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 23 | 26 | $6,630 | $2,710 | 40.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $5,225 | $2,177 | 41.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 30 | 33 | $3,960 | $2,105 | 53.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 54 | 126 | $30,240 | $14,137 | 46.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 139 | $24,325 | $11,079 | 45.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 64 | 90 | $10,800 | $4,874 | 45.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 35 | 35 | $9,625 | $4,039 | 42.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 38 | $7,030 | $3,096 | 44.0% |
About Dr. Jeffrey Letzer, DO
Dr. Jeffrey Letzer, DO is a Hematology & Oncology healthcare provider based in Fort Wayne, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760481766.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Letzer, DO has received a total of $43,943 in payments from pharmaceutical and medical device companies, with $6,330 received in 2024. These payments were reported across 136 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($23,775).
As a Medicare-enrolled provider, Letzer has provided services to 1,210 Medicare beneficiaries, totaling 2,544 services with total Medicare billing of $221,004. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Fort Wayne, IN
- Active Since 07/20/2005
- Last Updated 03/27/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1760481766
Products in Payments
- XARELTO (Drug) $25,982
- Tazverik (Drug) $3,450
- Kyprolis (Biological) $2,767
- VENCLEXTA (Drug) $1,650
- MONJUVI (Drug) $1,455
- EPKINLY (Drug) $359.40
- CABLIVI (Biological) $229.79
- VONJO (Drug) $200.00
- Ultomiris (Drug) $162.61
- KEYTRUDA (Biological) $159.04
- REBLOZYL (Biological) $154.70
- DARZALEX (Biological) $135.70
- Venclexta (Drug) $126.04
- Yescarta (Drug) $124.89
- Zydelig (Drug) $119.57
- Tavalisse (Drug) $109.99
- IMBRUVICA (Drug) $105.58
- ZYKADIA (Drug) $92.78
- VYXEOS (Drug) $88.33
- ANDEXXA (Drug) $70.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fort Wayne
Sunil Babu, M.d, M.D
Hematology & Oncology — Payments: $257,612
Hematology & Oncology $257,612
Dolly Quispe Leveau, M.d, M.D
Hematology & Oncology — Payments: $73,162
Hematology & Oncology $73,162
Dr. Robert Manges, Md, MD
Hematology & Oncology — Payments: $42,660
Hematology & Oncology $42,660
Farrukh Adhami, Md, MD
Hematology & Oncology — Payments: $35,244
Hematology & Oncology $35,244
Dr. Murugavel Muthusamy, M.d, M.D
Hematology & Oncology — Payments: $23,326
Hematology & Oncology $23,326
Melanie Clark
Hematology & Oncology — Payments: $15,035
Hematology & Oncology $15,035